NCT04809506

Brief Summary

The main goal of this project is to constitute a collection of biological samples, obtained through the clinical activity of the Centre for Screening and Prevention of Atherosclerosis at Toulouse University Hospital, managing patients in primary or secondary prevention for cardiovascular (CV) diseases. The main objective is to validate new biomarkers with prognostic value regarding the onset of future CV events. Besides, the biological collection will enable patho-physiological studies on atherosclerosis related diseases.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,500

participants targeted

Target at P75+ for all trials

Timeline
94mo left

Started Feb 2021

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress40%
Feb 2021Feb 2034

Study Start

First participant enrolled

February 4, 2021

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

March 11, 2021

Completed
11 days until next milestone

First Posted

Study publicly available on registry

March 22, 2021

Completed
8.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 3, 2030

Expected
4 years until next milestone

Study Completion

Last participant's last visit for all outcomes

February 3, 2034

Last Updated

March 19, 2026

Status Verified

March 1, 2026

Enrollment Period

9 years

First QC Date

March 11, 2021

Last Update Submit

March 16, 2026

Conditions

Cardiovascular Diseases

Keywords

Arterial diseaseatherosclerosisThrombosisBiomarkersGenetic polymorphisms

Outcome Measures

Primary Outcomes (2)

  • measurement of the candidate biomarker

    measurement, at baseline of the candidate biomarker, with respect to the onset, during follow-up, of a cardiovascular event: either coronary events or cerebrovascular stroke or lower limb arteriopathy.

    Day 0

  • measurement of the candidate biomarker

    measurement, at baseline of the candidate biomarker, with respect to the onset, during follow-up, of a cardiovascular event: either coronary events or cerebrovascular stroke or lower limb arteriopathy.

    during the intervention/procedure/surgery

Secondary Outcomes (2)

  • evolution of clinical and biological parameters involved in atherothrombosis

    Day 0

  • evolution of clinical and biological parameters involved in atherothrombosis

    during the intervention/procedure/surgery

Study Arms (1)

Patient consulting the Centre for Screening and Prevention of Atherosclerosis

2 additional blood samples (2 x 7ml) at every visit

Biological: additional blood samples

Interventions

additional blood samplesBIOLOGICAL

2 additional blood samples (2 x 7ml) at every visit

Patient consulting the Centre for Screening and Prevention of Atherosclerosis

Eligibility Criteria

Age18 Years - 99 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients consulting the Centre for Screening and Prevention of Atherosclerosis (CDPA) for management of their cardiovascular risk factors; patients on primary prevention, free of personal history of coronary artery disease, stroke or lower limb arteriopathy, or patients on secondary prevention having presented one of the above mentioned diseases

You may qualify if:

  • Adults over 18 yrs;
  • consulting the Centre for Screening and Prevention of Atherosclerosis (CDPA) for management of their cardiovascular risk factors;
  • patients on primary prevention, free of personal history of coronary artery disease, stroke or lower limb arteriopathy, or patients on secondary prevention having presented one of the above mentioned diseases;
  • patients affiliated to a health insurance system;
  • patients having given their written informed consent for a participation to the study and for possible genetic analysis of their personal traits.

You may not qualify if:

  • Patients under the age of 18;
  • patients being under legal protection

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospital Toulouse

Toulouse, 31059, France

RECRUITING

MeSH Terms

Conditions

Cardiovascular DiseasesAtherosclerosisThrombosis

Condition Hierarchy (Ancestors)

ArteriosclerosisArterial Occlusive DiseasesVascular DiseasesEmbolism and Thrombosis

Study Officials

  • Jean Ferrieres, MD PhD

    University Hospital, Toulouse

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Jean Ferrières, MD PhD

CONTACT

562323728ferrieres.j@chu-toulouse.fr

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 11, 2021

First Posted

March 22, 2021

Study Start

February 4, 2021

Primary Completion (Estimated)

February 3, 2030

Study Completion (Estimated)

February 3, 2034

Last Updated

March 19, 2026

Record last verified: 2026-03

Data Sharing

IPD Sharing
Will not share

Locations

FR(1)